

OXA-23 K-SeT



www.corisbio.com
IFU-58R7/EN/03

Manufacturer:

Coris BioConcept
CREALYS Science Park
Rue Guillaume Fouquet, 11
5032 GEMBLOUX
BELGIUM
Tel.: +32(0)81.719.917
Fax: +32(0)81.719.919
info@corisbio.com
Produced in BELGIUM

In vitro rapid diagnostic test for the detection of OXA-23 carbapenemase in bacterial culture

**FOR IN VITRO DIAGNOSTIC USE
FOR PROFESSIONAL USE ONLY**

EN

References: K-15R7, 20 cassettes, buffer, 20 tubes and droppers

I. INTRODUCTION

Acinetobacter baumannii is an important opportunistic and multidrug-resistant Gram-negative bacterium responsible for nosocomial infections in health facilities. If left untreated, this infection can lead to septicemia and death. The carbapenem-hydrolysing oxacillinases (OXAs) are the most commonly reported carbapenem-resistance determinants in *Acinetobacter* spp., particularly in *A. baumannii*. Among the OXAs, OXA-23 is the most prevalent carbapenem-resistance determinant in *A. baumannii* isolates.

OXA-23 has been detected in other bacterial species as chromosomal (*P. mirabilis*, Bonnet et al 2002 and Osterblad et al 2016; *A. radioresistans*) or plasmidic gene (*E. coli*, La et al, 2014), which can constitute reservoirs for horizontal transmission of this resistance factor (Poirel et al 2016). The detection of this resistance factor OXA-23, not only in resistant species but also in carrier species, is therefore of paramount importance in the control of antibiotic resistance in the hospital.

Nowadays, definitive confirmation of OXA-23 relies on molecular amplification analysis and DNA sequencing. These tests are expensive and can only be performed in dedicated environment and by skilled staff, hence limiting their more generalized usage.

The development of new rapid diagnostic tests to track antimicrobial resistance patterns is considered as one of the priority core action by international experts and health authorities.

The OXA-23 K-SeT test aimed at a rapid identification of the OXA-23 carbapenemase (and variants of the OXA-23 group) ensures effective treatment of patients and prevention of spread of OXA-23 *Acinetobacter* spp. carrier, especially in hospitals.

II. PRINCIPLE OF THE TEST

This test is ready to use and is based on a membrane technology with colloidal gold nanoparticles. A nitrocellulose membrane is sensitized with a monoclonal antibody directed against one epitope of the OXA-23 carbapenemase. Another monoclonal antibody directed against a second epitope of the OXA-23 carbapenemase is conjugated to colloidal gold particles. This conjugate is dried on a membrane.

This test is aimed at the detection of OXA-23 like carbapenemases in a single bacterial colony growing on agar plate. The sample must be diluted in the dilution buffer supplied with the test. When the provided buffer containing the resuspended bacteria comes into contact with the strip, the solubilized conjugate migrates with the sample by passive diffusion and both the conjugate and sample material come into contact with the anti-OXA-23 antibody that it is adsorbed onto the nitrocellulose strip. If the sample contains the OXA-23 carbapenemase, the conjugate-OXA-23 complex will remain bound to the anti-OXA-23 antibody adsorbed onto the nitrocellulose and a red line will develop. Solution continues to migrate to reach a second reagent (control reagent) that binds the migration control conjugate, thereby producing a red control line that confirms that the test is valid. Result is visible within 15 minutes.

III. REAGENTS AND MATERIALS

1. OXA-23 K-SeT (20)

20 sealed pouches containing one device and one desiccant. Each device contains one sensitized strip.

2. LY-A buffer vial (15 mL)

Saline solution buffered to pH 7.5 containing TRIS, NaN₃ (<0,1%) and a detergent.

3. Instruction for use (1)

4. Semi-rigid disposable collection tubes with droppers (20)

5.

IV. SPECIAL PRECAUTIONS

- All operations linked to the use of the test must be performed in accordance with Good Laboratory Practices (GLP).

- All reagents are for *in vitro* diagnostic use only.

- Pouch must be opened with care.

- Avoid touching nitrocellulose with your fingers.

- Wear gloves when handling samples.

- Never use reagents from another kit.

- Green lines indicate immunoreagents adsorption sites. Green colour disappears during the test.

- Reagents' quality cannot be guaranteed beyond their shelf-life dates or if reagents are not stored under required conditions as indicated in the insert.

V. WASTE DISPOSAL

- Dispose of gloves, swabs, test tubes and used devices in accordance with GLP.

- Each user is responsible for the management of any waste produced, and must ensure that it is disposed of in accordance with the applicable legislation.

VI. STORAGE

- An unopened pouch may be kept at between 4 and 30°C and used until the shelf-life date indicated on the packaging. Once the pouch is opened, run the test immediately.

- Avoid freezing devices and buffer.

VII. SPECIMEN HANDLING AND COLLECTION

Specimens to be tested should be obtained and handled by standard microbiological methods.

Make sure that the specimens are not treated with solutions containing formaldehyde or its derivatives.

Culture media tested and validated with Coris BioConcept RESIT kits are listed on the website: <https://www.corisbio.com/Products/Human-Field/OXA-23/FAQ.php>

VIII. PROCEDURE

PREPARATIONS OF THE TEST:


Allow kit components, in unopened packaging, and specimens (in case the plate containing colony to be tested was kept at 4°C) to reach room temperature (15-30°C) before performing a test.

Open the pouch and remove the device. Once opened, run the test immediately. Indicate the patient's name or specimen number on the device (one device per sample).

SPECIMEN PREPARATION PROCEDURE:

We recommend the use of fresh bacterial colonies for optimal test performance.

1. Prepare one semi-rigid tube provided in the kit and add **10 drops** of LY-A buffer in the tube.
2. Harvest bacteria by taking one colony with a disposable bacteriological loop and dip the loop in the bottom of the semi-rigid tube containing the buffer.
3. Stir thoroughly before removing the loop
4. Insert tightly the dropper on the semi-rigid tube.
5. Vortex the preparation to homogenize. The entire bacterial colony must be suspended into the buffer.
6. Invert the test tube and add slowly **3 drops** of diluted sample into the sample well of the cassette. Alternatively, add 100µl with a micropipette into the sample well of the cassette.
7. Allow to react for 15 min max and read the result.



Positive results may be reported as soon as the test and control lines become visible. **Do not take the appearance of new lines into account after the reaction time is passed.**

The result must be read on still wet strip.

IX. INTERPRETING RESULTS


The results are to be interpreted as follows:

Negative test result: a reddish-purple line appears across the central reading window at the Control line (C) position. No other band is present.

Positive test result: in addition to a reddish-purple band at the Control line (C), a visible reddish-purple band appears at the Test line position (T). Intensity of the test line may vary according to the quantity of antigens present in the sample. Any reddish-purple line (T), even weak, should be considered as a positive result.

Invalid test result: The absence of a Control line indicates a failure in the test procedure. Repeat invalid tests with a new test device.

Note: during the drying process, a very faint shadow may appear at the Test line position. It should not be regarded as a positive result.



X. PERFORMANCE

A. Detection Limit

The detection limit was determined with a purified recombinant OXA-23 protein and has been evaluated at 0,156 ng/mL.

B. Validation on collection of reference strains

The OXA-23 K-SeT was evaluated on a collection of 108 clinical isolates of carbapenem-resistant *Acinetobacter* spp. fully characterized resistance mechanisms to beta-lactams by phenotypic and molecular tests (Germany).

108 strains	35 strains tested positive with the OXA-23 K-SeT	35 strains carrying OXA-23 carbapenemase	<i>Acinetobacter baumannii</i> , <i>Acinetobacter pittii</i> , <i>Acinetobacter nosocomialis</i> , <i>Acinetobacter radioresistens</i>
	73 strains tested negative with the OXA-23 K-SeT	68 strains carrying a non-OXA-23 carbapenemase	OXA-40, OXA-51, OXA-58, OXA-143, OXA-235
		5 strains carrying class B carbapenemases	Including VIM-2, NDM-1, NDM-2

A second evaluation was retrospectively performed on 448 clinical strains of *Acinetobacter* spp. and 14 oxacillinase-producing Gram-negative bacteria collected in Belgium and in Italy between 2008 and 2018 with an agreement of 100 % versus real-time PCR and molecular sequencing. See Riccobono, 2019

	Italy	Belgium	Total	Test OXA-23 K-SeT
<i>bla</i> _{OXA-23-like}	170	137	307	307 +
<i>bla</i> _{OXA-24-like}	5	25	30	negative
<i>bla</i> _{OXA-58-like}	1	30	31	negative
<i>ISAba1 bla</i> _{OXA-51-like}	11	0	11	negative
<i>bla</i> _{OXA-23-like} + <i>bla</i> _{OXA-58-like}	5	2	7	7 +
<i>bla</i> _{OXA-23-like} + <i>ISAba1</i>	4	0	4	4 +
<i>bla</i> _{OXA-51-like}				
<i>bla</i> _{OXA-23-like} + <i>bla</i> _{NDM}	0	3	3	3 +
<i>bla</i> _{OXA-58-like} + <i>bla</i> _{VIM}	0	1	1	negative
<i>bla</i> _{NDM}	0	13	13	negative
<i>bla</i> _{OXA-143-like}	0	1	1	negative
<i>bla</i> _{IMP}	0	3	3	negative
<i>bla</i> _{VIM}	0	1	1	negative
<i>bla</i> _{GES}	0	1	1	negative
<i>bla</i> _{OXA-48-like}	0	2	2	negative
<i>bla</i> _{OXA-198-like}	0	1	1	negative
<i>non-carbapenemase producer</i>	0	46	46	negative
Total	196	266	462	321 +

C. Repeatability and reproducibility

To check intra-batch accuracy (repeatability), the same positive samples and a buffer solution were processed 15 times on kits of the same production batch in the same experimental conditions. All observed results were confirmed as expected.

To check inter-batch accuracy (reproducibility), some samples (positive and buffer) were processed on kits from three different production batches. All results were confirmed as expected.

XI. LIMITS OF THE KIT

The test is qualitative and cannot predict the quantity of antigens present in the sample. Clinical presentation and other test results must be taken into consideration to establish diagnosis.

A positive test does not rule out the possibility that other antibiotic resistance mechanisms may be present.

XII. TECHNICAL PROBLEMS/COMPLAINTS

If you encounter a technical problem or if performances do not correspond with those indicated in this package insert:














1. Record the kit batch number
2. If possible, keep the sample in the appropriate storage condition during the complaint management
3. Contact Coris BioConcept (client.care@corisbio.com) or your local distributor

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

XIII. BIBLIOGRAPHIC REFERENCES

- A. E. Riccobono, P. Bogaerts, A. Antonelli, S. Evrard, T. Giani, G. M. Rossolini and Y. Glupczynski. Evaluation of the OXA-23 K-SeT immunochromatographic assay for the rapid detection of OXA-23-like carbapenemase-producing *Acinetobacter* spp. *J Antimicrob Chemother.* 2019 Jan 25. doi: 10.1093
- B. DW. Wareham, LM. Phee, MHF. Abdul Momin. Direct detection of carbapenem resistance determinants in clinical specimens using immunochromatographic lateral flow devices. *J Antimicrob Chemother.* 2018 Mar 22. doi: 10.1093
- C. A. Saleh, S. Göttig and A. Hamprecht. Multiplex immunochromatographic detection of OXA-48, KPC and NDM carbapenemases: impact of the inoculum, antibiotics and agar. *J Clin Microbiol.* 2018 Feb 14. pii: JCM.00050-18.
- D. G. L. Vanstone, S. Woodhead, K. Roulston, H. Sharma, E. Wey, E. R. Smith, D. Mack and I. Balakrishna. Improving the detection of carbapenemase-producing organisms (CPO) in a low-prevalence setting: evaluation of four commercial methods and implementation of an algorithm of testing. *Journal of Medical Microbiology* 2018;67: 208–214
- E. P. Bogaerts, S. Evrard, L. Denorme, Q. Gillemann, P. Mertens, T.-D. Huang, and Y. Glupczynski. Evaluation of a new lateral flow assay for the detection of VIM-producing bacteria. 37th RICA, Paris, December, 18-19, 2017, Abstract # P066.
- F. Y. Glupczynski, A. Jousset, S. Evrard, R. Bonnin, T. Huang, L. Dortet, P. Bogaerts and T. Naas. Prospective evaluation of the OKN K-SeT assay, a new multiplex immunochromatographic test for the rapid detection of OXA-48-like, KPC and NDM carbapenemases. *J Antimicrob Chemother.* 2017 Jul 1 ;72(7):1955-1960
- G. CS. Nodari, AC. Gales, AL. Barth, CM. Magagnin, AP. Zavascki, CG. Carvalhaes. Detection of OXA-370 Directly from Rectal Swabs and Blood Culture Vials Using an Immunochromatographic Assay. *J Microbiol Methods.* 2017 May 5. pii: S0167-7012 : 30113-6
- H. Y. Glupczynski, A. Jousset, S. Evrard, R. Bonnin, TD Huang, L. Dortet, P. Bogaerts and T. Naas. Evaluation of a new multiplex immunochromatographic assay OKN K-SeT for the rapid detection of OXA-48, KPC and NDM carbapenemases from cultured bacteria. 27th European Congress of Clinical Microbiology and Infectious Diseases, Infectious Diseases April 22 – 25, 2017
- I. C. Trouvé, R. De Smedt and E. De Laer. Evaluation of five commercial confirmation tests for Carbapenemase-Producing Enterobacteriaceae in an OXA-48 endemic geographic region. 27th European Congress of Clinical Microbiology and Infectious Diseases, Infectious Diseases April 22 – 25, 2017
- J. E. Riccobono, A. Antonelli, P. Pecile, P. Bogaerts, MM. D'Andrea, GM. Rossolini. Evaluation of the KPC K-SeTVR immunochromatographic assay for the rapid detection of KPC carbapenemase producers from positive blood cultures. *J Antimicrob Chemother.* 2017 Nov 8. doi: 10.1093
- K. AC. Ramos, AC. Gales, J. Monteiro, S. Silbert, T. Chagas-Neto, AMO. Machado, CG. Carvalhaes. Evaluation of a rapid immunochromatographic test for detection of distinct variants of *Klebsiella pneumoniae* carbapenemase (KPC) in Enterobacteriaceae. *J Microbiol Methods.* 2017 Nov;142:1-3
- L. F. Erdem, A. Abulaila, Z. Aktas, O. Oncul. Comparison of the Novel Oxa-48 and Kpc K-SeT Assay, and Blue-Carba Test for the Detection of Carbapenemase-Producing Enterobacteriaceae Using PCR as a Reference Method. *Clin Lab.* 2017 Mar 1;63(3):515-522.
- M. DW. Wareham and MH. Abdul Momin. Rapid Detection of Carbapenemases in Enterobacteriaceae: Evaluation of the RESIST-3 O.K.N. (OXA-48, KPC, NDM) Multiplexed Lateral Flow Assay. *J Clin Microbiol.* 2017 Feb 1. pii: JCM.02471-16
- N. E. Rubio, Y. Zboromyrska, C. Pitart, I. Campo, I. Alejo-Cancho, A. Fasanella, A. Vergara, F. Marco, J. Vila. Evaluation of a rapid immunochromatographic test for the detection of OXA-48 carbapenemase. *Diagn Microbiol Infect Dis.* 2017 Mar;87(3):266-267
- O. F. Koroska, S. Göttig, M. Kaase, J. Steinmann, S. Gattermann, J. Sommer, T. Wille, G. Plum, A. Hamprecht. Comparison of phenotypic tests and an immunochromatographic assay and development of a new algorithm for OXA-48-like detection. *J Clin Microbiol.* 2016 Dec 28. Pii: JCM.01929-16
- P. F. Pasteran, L. Denorme, I. Ote, S. Gomez, D. De Belder, Y. Glupczynski, P. Bogaerts, B. Ghiglione, P. Power, P. Mertens, A. Corso. Rapid identification of OXA-48 and OXA-163 subfamily in carbapenem resistant gram-negative bacilli with a novel immunochromatographic lateral flow assay. *J Clin Microbiol.* 2016 Aug; 54(11):2832-2836
- Q. D. Meunier, A. Vickers, R. Pike, R.L. Hill, N. Woodford and K.L. Hopkins. Evaluation of the K-SeT R.E.S.I.S.T. immunochromatographic assay for the rapid detection of KPC and OXA-48-like carbapenemases. *J Antimicrob Chemother.* 2016 Aug; 71 (8):2357-9
- R. Wareham DW, Shah R, Betts JW, Phee LM, Abdul Momin MH. Evaluation of an Immunochromatographic Lateral Flow Assay (OXA-48 K-SeT) for the Rapid Detection of OXA-48-like Carbapenemases in Enterobacteriaceae. *J Clin Microbiol.* 2016 Feb;54 (2):471-3
- S. Fernández J, Fleites A, Rodicio MR, Vazquez F. Evaluation of OXA-48 K-Se T: an immunochromatographic assay for rapid detection of OXA-48-producing Enterobacteriaceae. *Diagn Microbiol Infect Dis.* 2016 May;85 (1):12-5
- T. Dortet L, Jousset A, Sainte-Rose V, Cuzon G, Naas T. Prospective evaluation of the OXA-48 K-SeT assay, an immunochromatographic test for the rapid detection of OXA-48-type carbapenemases. *J Antimicrob Chemother.* 2016 Jul;71 (7):1834-40
- U. Glupczynski Y, Evrard S, Ote I, Mertens P, Huang TD, Lecleptoux T, Bogaerts P. Evaluation of two new commercial immunochromatographic assays for the rapid detection of OXA-48 and KPC carbapenemases from cultured bacteria. *J Antimicrob Chemother.* 2016 May;71(5):1217-22
- V. B.M. Willey, X. Trimi, R. Ioboni, D.A. Boyd, G. Ricci, D.N. Grohn, D. Terenzi, A. Mazzulli, L. Mataseje, M. Mulvey, P. Lo, T. Mazzulli, S.M. Poutanen. The Coris BioConcept OXA48 K-SeT Immuno-Chromatographic Assay Detects OXA48-type Carbapenemases with High Sensitivity and Specificity. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam April 9-12, 2016
- W. P. Bogaerts, S. Evrard, G. Cuzon, TD. Huang, T. Naas and Y. Glupczynski. Specificity of the OXA-48 immunochromatographic K-SeT for the detection of OXA-48 like in *Shewanella* spp. 26th European Congress of Clinical Microbiology and Infectious Diseases, Infectious Amsterdam April 09 – 12, 2016

Last update: 20 FEBRUARY 2023

	Catalogue number		Manufacturer
	In vitro diagnostic medical device		Temperature limits
	Contains sufficient for <n> tests		Lot number
	Consult instructions for use		Do not reuse
	Keep dry		Use by
	Diluent specimen		Contains Sodium azide
	Unique device identifier		